Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
REGULATORY
Health Ministry Presents Proposal to Revise Priority Infectious Diseases
The Ministry of Health, Labor and Welfare (MHLW) has proposed revised definitions for the previously divided five groups of “priority infectious diseases,” along with an updated list of diseases that would be included in each category. Priority infectious diseases are…
To read the full story
Related Article
- Japan Eyes Priority Review for MCMs, Bill Submission Planned for 2027
October 28, 2026
- MHLW to Discuss Faster MCM Approvals during Health Emergencies
October 26, 2026
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
August 20, 2025
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- MHLW Council Endorses Early Approval Scheme for Medical Countermeasures
October 2, 2024
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
REGULATORY
- PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
- Drug Makers Can Refuse Diabetes Drug Supply over Improper Prescribing: JFTC
October 30, 2026
- Chuikyo Reps Back More Pharma Access to CEA Deliberations, Urge Neutrality
October 29, 2026
- FY2027 Revision: HCPs Press for Action on Drug Shortages, Negative Margins
October 29, 2026
- Zolgensma Cost-Effectiveness Analysis to Resume after Five-Year Halt
October 29, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…